BG105905A - Състав с контролирано освобождаване за лечение нахронична обструктивна белодробна болест - Google Patents

Състав с контролирано освобождаване за лечение нахронична обструктивна белодробна болест Download PDF

Info

Publication number
BG105905A
BG105905A BG105905A BG10590501A BG105905A BG 105905 A BG105905 A BG 105905A BG 105905 A BG105905 A BG 105905A BG 10590501 A BG10590501 A BG 10590501A BG 105905 A BG105905 A BG 105905A
Authority
BG
Bulgaria
Prior art keywords
composition
inhibitor
pde4
amount
rolipram
Prior art date
Application number
BG105905A
Other languages
Bulgarian (bg)
English (en)
Inventor
Patrick FAULKNER
Jaime LUCCA
Thomas WRZOSEK
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105905A publication Critical patent/BG105905A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105905A 1999-02-23 2001-09-14 Състав с контролирано освобождаване за лечение нахронична обструктивна белодробна болест BG105905A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12129199P 1999-02-23 1999-02-23
PCT/US2000/004713 WO2000050011A1 (en) 1999-02-23 2000-02-22 Controlled release formulation for treating copd

Publications (1)

Publication Number Publication Date
BG105905A true BG105905A (bg) 2002-04-30

Family

ID=22395738

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105905A BG105905A (bg) 1999-02-23 2001-09-14 Състав с контролирано освобождаване за лечение нахронична обструктивна белодробна болест

Country Status (29)

Country Link
US (1) US20030211152A1 (sk)
EP (1) EP1154758A4 (sk)
JP (1) JP2002537320A (sk)
KR (1) KR20010112279A (sk)
CN (1) CN1195496C (sk)
AR (1) AR028986A1 (sk)
AU (1) AU3501500A (sk)
BG (1) BG105905A (sk)
BR (1) BR0008382A (sk)
CA (1) CA2366747A1 (sk)
CO (1) CO5150233A1 (sk)
CZ (1) CZ20013025A3 (sk)
EA (1) EA200100906A1 (sk)
HK (1) HK1043045A1 (sk)
HU (1) HUP0200134A3 (sk)
ID (1) ID29792A (sk)
IL (1) IL144603A0 (sk)
MA (1) MA25386A1 (sk)
MY (1) MY121142A (sk)
NO (1) NO20014049L (sk)
NZ (1) NZ527716A (sk)
OA (1) OA11836A (sk)
PE (1) PE20001496A1 (sk)
PL (1) PL350287A1 (sk)
SK (1) SK12072001A3 (sk)
TR (1) TR200102448T2 (sk)
TW (1) TWI224013B (sk)
WO (1) WO2000050011A1 (sk)
ZA (1) ZA200106803B (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3249A1 (fr) * 1999-10-29 2001-05-10 Smithkline Beecham Corp Procédé d'administration d'un inhibiteur phosphodiesterase 4
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
BR0212582A (pt) * 2001-09-19 2004-10-13 Altana Pharma Ag Combinação
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1667661A1 (en) * 2003-09-30 2006-06-14 Lupin Limited Extended release formulation of beta-lactam antibiotics
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
BRPI0513846A (pt) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
EP3911304B1 (en) * 2019-01-15 2023-09-06 UNION therapeutics A/S Modified release tablet formulations containing phosphodiesterase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297088A (sk) * 1961-01-31
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
NO20014049D0 (no) 2001-08-20
SK12072001A3 (sk) 2002-01-07
OA11836A (en) 2005-08-22
CN1195496C (zh) 2005-04-06
HUP0200134A3 (en) 2003-03-28
CN1347314A (zh) 2002-05-01
TWI224013B (en) 2004-11-21
HUP0200134A2 (hu) 2002-05-29
CA2366747A1 (en) 2000-08-31
TR200102448T2 (tr) 2003-03-21
WO2000050011A1 (en) 2000-08-31
PL350287A1 (en) 2002-12-02
ID29792A (id) 2001-10-11
JP2002537320A (ja) 2002-11-05
NO20014049L (no) 2001-10-22
HK1043045A1 (zh) 2002-09-06
KR20010112279A (ko) 2001-12-20
EP1154758A4 (en) 2007-09-05
ZA200106803B (en) 2002-08-19
CZ20013025A3 (cs) 2002-07-17
BR0008382A (pt) 2002-02-05
MY121142A (en) 2005-12-30
AU3501500A (en) 2000-09-14
IL144603A0 (en) 2002-05-23
NZ527716A (en) 2005-03-24
EA200100906A1 (ru) 2002-02-28
US20030211152A1 (en) 2003-11-13
CO5150233A1 (es) 2002-04-29
EP1154758A1 (en) 2001-11-21
AR028986A1 (es) 2003-06-04
PE20001496A1 (es) 2001-02-08
MA25386A1 (fr) 2002-04-01

Similar Documents

Publication Publication Date Title
US4753801A (en) Sustained release tablets
JP4885896B2 (ja) レボドパ／カルビドパ／エンタカポン医薬製剤
US8216610B2 (en) Oral paracetamol formulations
KR960006067B1 (ko) 경구 투여용 서방성 약학 제제
BG105905A (bg) Състав с контролирано освобождаване за лечение нахронична обструктивна белодробна болест
US20080226713A1 (en) Controlled Release Pharmaceutical Compositions of Tolperisone for Oral Administration
SK4862002A3 (en) Extended release formulations of erythromycin derivatives
KR20050075408A (ko) 트라마돌 및 토피라메이트를 포함하는 방출 조절형 제제
US20050276847A1 (en) Oral delivery system
EP2089002A1 (en) Phenylalkyl carbamate compositions
AU772909B2 (en) Method for administering a phosphodiesterase 4 inhibitor
EP2148655B1 (en) Pharmaceutical compositions of clopidogrel
US6713509B1 (en) Controlled release formulation for treating COPD
WO2020148219A1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
US20050048118A1 (en) Modified release venlafaxine hydrochloride tablets
JP2022517616A (ja) ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
MXPA01008523A (en) Controlled release formulation for treating copd
AU2004201503A1 (en) Controlled Release Formulation for Treating COPD
CA3238703A1 (en) A film coated tablet comprising micronized tofacitinib
JP3850473B2 (ja) 持続性錠剤
ZA200203349B (en) Method for administering a phosphodiesterase 4 inhibitor.